Idealized PPARγ-based therapies: Lessons from bench and bedside

PPAR Research

Volumn , Issue , 2012, Pages

  Amato, Angelica Amorim ^a   De Assis Rocha Neves, Francisco ^a  

^a UNIVERSITY OF BRASILIA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROSIGLITAZONE; TROGLITAZONE;

BLADDER CANCER; BONE ATROPHY; BONE DENSITY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE; DRUG EFFICACY; DRUG RECALL; DRUG SAFETY; FLUID RETENTION; FRACTURE; GLUCOSE HOMEOSTASIS; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; LIPID METABOLISM; LIVER TOXICITY; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PERIPHERAL EDEMA; PLASMA VOLUME; REVIEW; SIDE EFFECT; VASCULITIS; WEIGHT GAIN;

EID: 84863696316     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2012/978687     Document Type: Review

References (104)

1. Chawla A., Repa J. J., Evans R. M., Mangelsdorf D. J., Nuclear receptors and lipid physiology: opening the x-files Science 2001 294 5548 1866 1870 (Pubitemid 33101573)
2. Evans R. M., Barish G. D., Wang Y. X., PPARs and the complex journey to obesity Nature Medicine 2004 10 4 355 361 (Pubitemid 38508511)
3. Zoete V., Grosdidier A., Michielin O., Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators Biochimica et Biophysica Acta 2007 1771 8 915 925 (Pubitemid 47208545)
4. Lehmann J. M., Moore L. B., Smith-Oliver T. A., Wilkison W. O., Willson T. M., Kliewer S. A., An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor (PPAR ) Journal of Biological Chemistry 1995 270 22 12953 12956
5. Tontonoz P., Spiegelman B. M., Fat and beyond: the diverse biology of PPAR Annual Review of Biochemistry 2008 77 289 312
6. Semple R. K., Chatterjee V. K. K., O'Rahilly S., PPAR and human metabolic disease Journal of Clinical Investigation 2006 116 3 581 589
7. Burant C. F., Sreenan S., Hirano K. I., Tai T. A. C., Lohmiller J., Lukens J., Davidson N. O., Ross S., Graves R. A., Troglitazone action is independent of adipose tissue Journal of Clinical Investigation 1997 100 11 2900 2908 (Pubitemid 28007561)
8. Gavrilova O., Haluzik M., Matsusue K., Cutson J. J., Johnson L., Dietz K. R., Nicol C. J., Vinson C., Gonzalez F. J., Reitman M. L., Liver peroxisome proliferator-activated receptor contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass Journal of Biological Chemistry 2003 278 36 34268 34276 (Pubitemid 37553270)
9. Kim J. K., Fillmore J. J., Gavrilova O., Chao L., Higashimori T., Choi H., Kim H. J., Yu C., Chen Y., Qu X., Haluzik M., Reitman M. L., Shulman G. I., Differential effects of rosiglitazone on skeletal muscle and liver insulin resistance in A-ZIP/F-1 fatless mice Diabetes 2003 52 6 1311 1318 (Pubitemid 36666182)
10. Khan M. A., Peter J. V. S., Xue J. L., A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone Diabetes Care 2002 25 4 708 711 (Pubitemid 41071191)
11. Yki-Jrvinen H., Thiazolidinediones The New England Journal of Medicine 2004 351 11 1106 1118
12. Grey A., Skeletal consequences of thiazolidinedione therapy Osteoporosis International 2008 19 2 129 137
13. Nissen S. E., Wolski K., Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes The New England Journal of Medicine 2007 356 24 2457 2471 (Pubitemid 46919772)
14. Lewis J. D., Ferrara A., Peng T., Hedderson M., Bilker W. B., Quesenberry C. P., Vaughn D. J., Nessel L., Selby J., Strom B. L., Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study Diabetes Care 2011 34 4 916 922
15. Piccinni C., Motola D., Marchesini G., Poluzzi E., Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting Diabetes Care 2011 34 6 1369 1371
16. Watkins P. B., Whitcomb R. W., Hepatic dysfunction associated with troglitazone The New England Journal of Medicine 1998 338 13 916 917
17. Nesto R. W., Bell D., Bonow R. O., Fonseca V., Grundy S. M., Horton E. S., Le Winter M., Porte D., Semenkovich C. F., Smith S., Young L. H., Kahn R., Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association Diabetes Care 2004 27 1 256 263 (Pubitemid 38196741)
18. Zhang H., Zhang A., Kohan D. E., Nelson R. D., Gonzalez F. J., Yang T., Collecting duct-specific deletion of peroxisome proliferator-activated receptor blocks thiazolidinedione-induced fluid retention Proceedings of the National Academy of Sciences of the United States of America 2005 102 26 9406 9411 (Pubitemid 40923576)
19. Guan Y., Hao C., Cha D. R., Rao R., Lu W., Kohan D. E., Magnuson M. A., Redha R., Zhang Y., Breyer M. D., Thiazolidinediones expand body fluid volume through PPAR stimulation of ENaC-mediated renal salt absorption Nature Medicine 2005 11 8 861 866 (Pubitemid 41161118)
20. Zanchi A., Chiolero A., Maillard M., Nussberger J., Brunner H. R., Burnier M., Effects of the peroxisomal proliferator-activated receptor- agonist pioglitazone on renal and hormonal responses to salt in healthy men Journal of Clinical Endocrinology and Metabolism 2004 89 3 1140 1145 (Pubitemid 38368402)
21. Guan Y., Zhang Y., Davis L., Breyer M. D., Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans American Journal of Physiology 1997 273 6 F1013 F1022
22. Yang T., Michele D. E., Park J., Smart A. M., Lin Z., Brosius F. C., Schnermann J. B., Briggs J. P., Expression of peroxisomal proliferator-activated receptors and retinoid X receptors in the kidney American Journal of Physiology 1999 277 6 F966 F973
23. Hong G., Lockhart A., Davis B., PPAR gamma activation enhances cell surface ENaCalpha via up-regulation of SGK1 in human collecting duct cells The FASEB Journal 2003 17 13 1966 1968
24. Chen L., Yang B., McNulty J. A., Clifton L. G., Binz J. G., Grimes A. M., Strum J. C., Harrington W. W., Chen Z., Balon T. W., Stimpson S. A., Brown K. K., GI262570, a peroxisome proliferator-activated receptor agonist, changes electrolytes and water reabsorption from the distal nephron in rats Journal of Pharmacology and Experimental Therapeutics 2005 312 2 718 725 (Pubitemid 40189571)
25. Yang B., Clifton L. G., McNulty J. A., Chen L., Brown K. K., Baer P. G., Effects of a PPAR agonist, GI262570, on renal filtration fraction and nitric oxide level in conscious rats Journal of Cardiovascular Pharmacology 2003 42 3 436 441 (Pubitemid 37071701)
26. Tiwari S., Blasi E. R., Heyen J. R., McHarg A. D., Ecelbarger C. M., Time course of AQP-2 and ENaC regulation in the kidney in response to PPAR agonists associated with marked edema in rats Pharmacological Research 2008 57 5 383 392
27. Yamakawa K., Hosoi M., Koyama H., Tanaka S., Fukumoto S., Morii H., Nishizawa Y., Peroxisome proliferator-activated receptor- agonists increase vascular endothelial growth factor expression in human vascular smooth muscle cells Biochemical and Biophysical Research Communications 2000 271 3 571 574 (Pubitemid 30444669)
28. Baba T., Shimada K., Neugebauer S., Yamada D., Hashimoto S., Watanabe T., The oral insulin sensitizer, thiazolidinedione, increases plasma vascular indothelial growth factor in type 2 diabetic patients Diabetes Care 2001 24 5 953 954 (Pubitemid 33636074)
29. Walker A. B., Naderali E. K., Chattington P. D., Buckingham R. E., Williams G., Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro Diabetes 1998 47 5 810 814 (Pubitemid 28201812)
30. Dormandi J. A., Charbonnel B., Eckland D. J., Erdmann E., Massi-Benedetti M., Moules I. K., Skene A. M., Tan M. H., Lefbvre P. J., Murray G. D., Standl E., Wilcox R. G., Wilhelmsen L., Betteridge J., Birkeland K., Golay A., Heine R. J., Kornyi L., Laakso M., Mok M., Norkus A., Pirags V., Podar T., Scheen A., Scherbaum W., Schernthaner G., Schmitz O., krha J., Smith U., Tato J., Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial The Lancet 2005 366 9493 1279 1289 (Pubitemid 41416583)
31. Gerstein H. C., Yusuf S., Bosch J., Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial The Lancet 2006 368 9541 1096 1105
32. Benbow A., Stewart M., Yeoman G., Thiazolidinediones for type 2 diabetes. All glitazones may exacerbate heart failure British Medical Journal 2001 322 7280 236
33. Ryan K. K., Li B., Grayson B. E., Matter E. K., Woods S. C., Seeley R. J., A role for central nervous system PPAR- in the regulation of energy balance Nature Medicine 2011 17 5 623 626
34. Lu M., Sarruf D. A., Talukdar S., Sharma S., Li P., Bandyopadhyay G., Nalbandian S., Fan W., Gayen J. R., Mahata S. K., Webster N. J., Schwartz M. W., Olefsky J. M., Brain PPAR- promotes obesity and is required for the insuling-sensitizing effect of thiazolidinediones Nature Medicine 2011 17 5 618 622
35. Kelly I. E., Han T. S., Walsh K., Lean M. E. J., Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes Diabetes Care 1999 22 3, article 536
36. Nakamura T., Funahashi T., Yamashita S., Nishida M., Nishida Y., Takahashi M., Hotta K., Kuriyama H., Kihara S., Ohuchi N., Nishimura T., Kishino B. I., Ishikawa K., Kawamoto T., Tokunaga K., Nakagawa C., Mineo I., Watanabe F., Tarui S., Matsuzawa Y., Thiazolidinedione derivative improves fat distribution and multiple risk factors in subjects with visceral fat accumulationdouble-blind placebo-controlled trial Diabetes Research and Clinical Practice 2001 54 3 181 190 (Pubitemid 33016325)
37. Miyazaki Y., Mahankali A., Matsuda M., Mahankali S., Hardies J., Cusi K., Mandarino L. J., DeFronzo R. A., Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients Journal of Clinical Endocrinology and Metabolism 2002 87 6 2784 2791 (Pubitemid 34655345)
38. Berger J. P., Petro A. E., Macnaul K. L., Kelly L. J., Zhang B. B., Richards K., Elbrecht A., Johnson B. A., Zhou G., Doebber T. W., Biswas C., Parikh M., Sharma N., Tanen M. R., Thompson G. M., Ventre J., Adams A. D., Mosley R., Surwit R. S., Moller D. E., Distinct properties and advantages of a novel peroxisome proliferator-activated protein selective modulator Molecular Endocrinology 2003 17 4 662 676 (Pubitemid 36403578)
39. Larsen P. J., Jensen P. B., Srensen R. V., Larsen L. K., Vrang N., Wulff E. M., Wassermann K., Differential influences of peroxisome proliferator- activated receptors and- on food intake and energy homeostasis Diabetes 2003 52 9 2249 2259 (Pubitemid 37059494)
40. Ghazzi M. N., Perez J. E., Antonucci T. K., Driscoll J. H., Huang S. M., Faja B. W., Whitcomb R. W., Cardiac and glycemic benefits of troglitazone treatment in NIDDM Diabetes 1997 46 3 433 439 (Pubitemid 27090272)
41. Shimoyama M., Ogino K., Tanaka Y., Ikeda T., Hisatome I., Hemodynamic basis for the acute cardiac effects of troglitazone in isolated perfused rat hearts Diabetes 1999 48 3 609 615 (Pubitemid 29106877)
42. Asakawa M., Takano H., Nagai T., Uozumi H., Hasegawa H., Kubota N., Saito T., Masuda Y., Kadowaki T., Komuro I., Peroxisome proliferator-activated receptor plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo Circulation 2002 105 10 1240 1246
43. Yamamoto K., Ohki R., Lee R. T., Ikeda U., Shimada K., Peroxisome proliferator-activated receptor activators inhibit cardiac hypertrophy in cardiac myocytes Circulation 2001 104 14 1670 1675 (Pubitemid 32947532)
44. Tsuji T., Mizushige K., Noma T., Murakami K., Ohmori K., Miyatake A., Kohno M., Pioglitazone improves left ventricular diastolic function and decreases collagen accumulation in prediabetic stage of a type II diabetic rat Journal of Cardiovascular Pharmacology 2001 38 6 868 874 (Pubitemid 33104697)
45. Yue T. L., Chen J., Bao W., Narayanan P. K., Bril A., Jiang W., Lysko P. G., Gu J. L., Boyce R., Zimmerman D. M., Hart T. K., Buckingham R. E., Ohlstein E. H., In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor- agonist rosiglitazone Circulation 2001 104 21 2588 2594 (Pubitemid 33104798)
46. Shiomi T., Tsutsui H., Hayashidani S., Suematsu N., Ikeuchi M., Wen J., Ishibashi M., Kubota T., Egashira K., Takeshita A., Pioglitazone, a peroxisome proliferator-activated receptor- agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction Circulation 2002 106 24 3126 3132 (Pubitemid 35440299)
47. Pickavance L. C., Tadayyon M., Widdowson P. S., Buckingham R. E., Wilding J. P. H., Therapeutic index for rosiglitazone in dietary obese rats: separation of efficacy and haemodilution British Journal of Pharmacology 1999 128 7 1570 1576
48. Arakawa K., Ishihara T., Aoto M., Inamasu M., Kitamura K., Saito A., An antidiabetic thiazolidinedione induces eccentric cardiac hypertrophy by cardiac volume overload in rats Clinical and Experimental Pharmacology and Physiology 2004 31 1-2 8 13
49. Duan S. Z., Ivashchenko C. Y., Russell M. W., Milstone D. S., Mortensen R. M., Cardiomyocyte-specffic knockout and agonist of peroxisome proliferator-activated receptor- both induce cardiac hypertrophy in mice Circulation Research 2005 97 4 372 379 (Pubitemid 41216142)
50. Sutton M. S. J., Rendell M., Dandona P., Dole J. F., Murphy K., Patwardhan R., Patel J., Freed M., A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes Diabetes care 2002 25 11 2058 2064
51. Home P. D., Pocock S. J., Beck-Nielsen H., Curtis P. S., Gomis R., Hanefeld M., Jones N. P., Komajda M., McMurray J. J., Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial The Lancet 2009 373 9681 2125 2135
52. Psaty B. M., Prentice R. L., Variation in event rates in trials of patients with type 2 diabetes Journal of the American Medical Association 2009 302 15 1698 1700
53. Nissen S. E., Setting the RECORD straight Journal of the American Medical Association 2010 303 12 1194 1195
54. Singh S., Loke Y. K., Furberg C. D., Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis Journal of the American Medical Association 2007 298 10 1189 1195 (Pubitemid 47403105)
55. Diamond G. A., Bax L., Kaul S., Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death Annals of Internal Medicine 2007 147 8 578 581 (Pubitemid 351664507)
56. Nissen S. E., Wolski K., Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality Archives of Internal Medicine 2010 170 14 1191 1201
57. Graham D. J., Ouellet-Hellstrom R., Macurdy T. E., Ali F., Sholley C., Worrall C., Kelman J. A., Risk of acute myocardial infarction, stroke, heart failure, and death in elderly medicare patients treated with rosiglitazone or pioglitazone Journal of the American Medical Association 2010 304 4 411 418
58. Juurlink D. N., Gomes T., Lipscombe L. L., Austin P. C., Hux J. E., Mamdani M. M., Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study British Medical Journal 2009 339
59. Mannucci E., Monami M., Lamanna C., Gensini G. F., Marchionni N., Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials Diabetes, Obesity and Metabolism 2008 10 12 1221 1238
60. Lincoff A. M., Wolski K., Nicholls S. J., Nissen S. E., Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials Journal of the American Medical Association 2007 298 10 1180 1188 (Pubitemid 47403104)
61. Goldberg R. B., Kendall D. M., Deeg M. A., Buse J. B., Zagar A. J., Pinaire J. A., Tan M. H., Khan M. A., Perez A. T., Jacober S. J., A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia Diabetes Care 2005 28 7 1547 1554 (Pubitemid 40923063)
62. Hsiao A., Worrall D. S., Olefsky J. M., Subramaniam S., Variance-modeled posterior inference of microarray data: detecting gene-expression changes in 3T3-L1 adipocytes Bioinformatics 2004 20 17 3108 3127 (Pubitemid 39619201)
63. Guo L., Zhang L., Sun Y., Muskhelishvili L., Blann E., Dial S., Shi L., Schroth G., Dragan Y. P., Differences in hepatotoxicity and gene expression profiles by anti-diabetic PPAR agonists on rat primary hepatocytes and human HepG2 cells Molecular Diversity 2006 10 3 349 360 (Pubitemid 44546687)
64. Wilson K. D., Li Z., Wagner R., Yue P., Tsao P., Nestorova G., Huang M., Hirschberg D. L., Yock P. G., Quertermous T., Wu J. C., Transcriptome alteration in the diabetic heart by rosiglitazone: implications for cardiovascular mortality PLoS ONE 2008 3 7
65. Schwartz A. V., Sellmeyer D. E., Vittinghoff E., Palermo L., Lecka-Czernik B., Feingold K. R., Strotmeyer E. S., Resnick H. E., Carbone L., Beamer B. A., Seok W. P., Lane N. E., Harris T. B., Cummings S. R., Thiazolidinedione use and bone loss in older diabetic adults Journal of Clinical Endocrinology and Metabolism 2006 91 9 3349 3354 (Pubitemid 44402103)
66. Grey A., Bolland M., Gamble G., Wattie D., Horne A., Davidson J., Reid I. R., The peroxisome proliferator-activated receptor- agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial Journal of Clinical Endocrinology and Metabolism 2007 92 4 1305 1310 (Pubitemid 46556402)
67. Yaturu S., Bryant B., Jain S. K., Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men Diabetes Care 2007 30 6 1574 1576 (Pubitemid 46876524)
68. http://www.fda.gov/MedWatch/index.html
69. Meier C., Kraenzlin M. E., Bodmer M., Jick S. S., Jick H., Meier C. R., Use of thiazolidinediones and fracture risk Archives of Internal Medicine 2008 168 8 820 825 (Pubitemid 351620084)
70. Habib Z. A., Havstad S. L., Wells K., Divine G., Pladevall M., Williams L. K., Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus Journal of Clinical Endocrinology and Metabolism 2010 95 2 592 600
71. Bilik D., McEwen L. N., Brown M. B., Pomeroy N. E., Kim C., Asao K., Crosson J. C., Duru O. K., Ferrara A., Hsiao V. C., Karter A. J., Lee P. G., Marrero D. G., Selby J. V., Subramanian U., Herman W. H., Thiazolidinediones and fractures: evidence from translating research into action for diabetes Journal of Clinical Endocrinology and Metabolism 2010 95 10 4560 4565
72. Ali A. A., Weinstein R. S., Stewart S. A., Parfitt A. M., Manolagas S. C., Jilka R. L., Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation Endocrinology 2005 146 3 1226 1235
73. Rzonca S. O., Suva L. J., Gaddy D., Montague D. C., Lecka-Czernik B., Bone is a target for the antidiabetic compound rosiglitazone Endocrinology 2004 145 1 401 406 (Pubitemid 38094536)
74. Lecka-Czernik B., Ackert-Bicknell C., Adamo M. L., Marmolejos V., Churchill G. A., Shockley K. R., Reid I. R., Grey A., Rosen C. J., Activation of peroxisome proliferator-activated receptor (PPAR ) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo Endocrinology 2007 148 2 903 911 (Pubitemid 46143190)
75. Wan Y., Chong L. W., Evans R. M., PPAR- regulates osteoclastogenesis in mice Nature Medicine 2007 13 12 1496 1503
76. El Hage J.,. 2005, http://www.fda.gov/ohrms/dockets/ac/05/slides/2005- 4169S20202-FDA-ElHage.ppt
77. El Hage J., Clinical and preclinical safety assessments for PPAR agonists. 2006, http://www.fda.gov/
78. Klaunig J. E., Babich M. A., Baetcke K. P., Cook J. C., Corton J. C., David R. M., DeLuca J. G., Lai D. Y., McKee R. H., Peters J. M., Roberts R. A., Fenner-Crisp P. A., PPAR agonist-induced rodent tumors: modes of action and human relevance Critical Reviews in Toxicology 2003 33 6 655 780 (Pubitemid 38037444)
79. Lubet R. A., Fischer S. M., Steele V. E., Juliana M. M., Desmond R., Grubbs C. J., Rosiglitazone, a PPAR gamma agonist: potent promoter of hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers International Journal of Cancer 2008 123 10 2254 2259
80. Rumi M. A. K., Ishihara S., Kazumori H., Kadowaki Y., Kinoshita Y., Can PRAR ligands be used in cancer therapy? Current Medicinal Chemistry 2004 4 6 465 477 (Pubitemid 39406260)
81. Oleksiewicz M. B., Thorup I., Nielsen H. S., Andersen H. V., Hegelund A. C., Iversen L., Guldberg T. S., Brinck P. R., Sjogren I., Thinggaard U. K., Jrgensen L., Jensen M. B., Generalized cellular hypertrophy is induced by a dual-acting PPAR agonist in rat urinary bladder urothelium in vivo Toxicologic Pathology 2005 33 5 552 560 (Pubitemid 41473090)
82. Cohen S. M., Effects of PPAR and combined agonists on the urinary tract of rats and other species Toxicological Sciences 2005 87 2 322 327 (Pubitemid 41300679)
83. http://www.fda.gov/Drugs/DrugSafety/ucm259150.htm
84. Ferrara A., Lewis J. D., Quesenberry C. P. Jr., Peng T., Strom B. L., Van Den Eeden S. K., Ehrlich S. F., Habel L. A., Cohort study of pioglitazone and cancer incidence in patients with diabetes Diabetes Care 2011 34 4 923 929
85. Nissen S. E., Wolski K., Topol E. J., Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus Journal of the American Medical Association 2005 294 20 2581 2586 (Pubitemid 41697247)
86. Willson T. M., Cobb J. E., Cowan D. J., Wiethe R. W., Correa I. D., Prakash S. R., Beck K. D., Moore L. B., Kliewer S. A., Lehmann J. M., The structure-activity relationship between peroxisome proliferator-activated receptor agonism and the antihyperglycemic activity of thiazolidinediones Journal of Medicinal Chemistry 1996 39 3 665 668
87. Sakamoto J., Kimura H., Moriyama S., Odaka H., Momose Y., Sugiyama Y., Sawada H., Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone Biochemical and Biophysical Research Communications 2000 278 3 704 711
88. Hall J. M., McDonnell D. P., The molecular mechanisms underlying the proinflammatory actions of thiazolidinediones in human macrophages Molecular Endocrinology 2007 21 8 1756 1768 (Pubitemid 47173789)
89. Herz M., Johns D., Reviriego J., Grossman L. D., Godin C., Duran S., Hawkins F., Lochnan H., Escobar-Jiménez F., Hardin P. A., Konkoy C. S., Tan M. H., A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus Clinical Therapeutics 2003 25 4 1074 1095 (Pubitemid 36532579)
90. Orasanu G., Ziouzenkova O., Devchand P. R., Nehra V., Hamdy O., Horton E. S., Plutzky J., The peroxisome proliferator-activated receptor- agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor- -dependent manner in vitro and in vivo in mice Journal of the American College of Cardiology 2008 52 10 869 881
91. Yen C.-J., Beamer B. A., Negri C., Silver K., Brown K. A., Yarnall D. P., Burns D. K., Roth J., Shuldiner A. R., Molecular scanning of the human peroxisome proliferator activated receptor (hPPAR ) gene in diabetic Caucasians: identification of a Pro12Ala PPAR 2 missense mutation Biochemical and Biophysical Research Communications 1997 241 2 270 274 (Pubitemid 28020091)
92. Masugi J., Tamori Y., Mori H., Koike T., Kasuga M., Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator- activated receptor- 2 on thiazolidinedione-induced adipogenesis Biochemical and Biophysical Research Communications 2000 268 1 178 182 (Pubitemid 30116630)
93. Deeb S. S., Fajas L., Nemoto M., Pihlajamaki J., Mykkanen L., Kuusisto J., Laakso M., Fujimoto W., Auwerx J., A Pro12Ala substitution in PPAR 2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity Nature Genetics 1998 20 3 284 287 (Pubitemid 28507675)
94. Lindi V. I., Uusitupa M. I. J., Lindstrm J., Louheranta A., Eriksson J. G., Valle T. T., Hmlinen H., Ilanne-Parikka P., Keinnen-Kiukaanniemi S., Laakso M., Tuomilehto J., Association of the Pro12Ala polymorphism in the PPAR- 2 gene with 3-year incidence of type 2 diabetes and body weight change in the finnish diabetes prevention study Diabetes 2002 51 8 2581 2586 (Pubitemid 34827410)
95. Altshuler D., Hirschhorn J. N., Klannemark M., Lindgren C. M., Vohl M. C., Nemesh J., Lane C. R., Schaffner S. F., Bolk S., Brewer C., Tuomi T., Gaudet D., Hudson T. J., Daly M., Groop L., Lander E. S., The common PPAR Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes Nature Genetics 2000 26 1 76 80
96. Pihlajamki J., Miettinen R., Valve R., Karjalainen L., Mykknen L., Kuusisto J., Deeb S., Auwerx J., Laakso M., The Pro12Ala substitution in the peroxisome proliferator activated receptor gamma 2 is associated with an insulin-sensitive phenotype in families with familial combined hyperlipidemia and in nondiabetic elderly subjects with dyslipidemia Atherosclerosis 2000 151 2 567 574 (Pubitemid 30618776)
97. Masud S., Ye S., Effect of the peroxisome proliferates activated receptor- gene Pro12Ala variant on body mass index: a meta-analysis Journal of Medical Genetics 2003 40 10 773 780 (Pubitemid 37311078)
98. Miles P. D. G., Barak Y., He W., Evans R. M., Olefsky J. M., Improved insulin-sensitivity in mice heterozygous for PPAR- deficiency Journal of Clinical Investigation 2000 105 3 287 292 (Pubitemid 30094448)
99. Miles P. D. G., Barak Y., Evans R. M., Olefsky J. M., Effect of heterozygous PPAR deficiency and TZD treatment on insulin resistance associated with age and high-fat feeding American Journal of Physiology 2003 284 3 E618 E626
100. Cock T. A., Houten S. M., Auwerx J., Peroxisome proliferator-activated receptor- : too much of a good thing causes harm EMBO Reports 2004 5 2 142 147 (Pubitemid 38401192)
101. Zhang F., Lavan B. E., Gregoire F. M., Selective modulators of PPAR- activity: molecular aspects related to obesity and side-effects PPAR Research 2007
102. Berger J. P., Akiyama T. E., Meinke P. T., PPARs: therapeutic targets for metabolic disease Trends in Pharmacological Sciences 2005 26 5 244 251 (Pubitemid 40603072)
103. Choi J. H., Banks A. S., Estall J. L., Kajimura S., Bostrm P., Laznik D., Ruas J. L., Chalmers M. J., Kamenecka T. M., Blher M., Griffin P. R., Spiegelman B. M., Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPAR 3 by Cdk5 Nature 2010 466 7305 451 456
104. Choi J. H., Banks A. S., Kamenecka T. M., Antidiabetic actions of a non-agonist PPAR gamma ligand blocking Cdk5-mediated phosphorylation Nature 2011 477 7365 477 481